Targeting prohibitins induces apoptosis in acute myeloid leukemia cells

Fluorizoline is a new synthetic molecule that induces apoptosis by selectively targeting prohibitins (PHBs). In this study, the pro-apoptotic effect of fluorizoline was assessed in two cell lines and 21 primary samples from patients with debut of acute myeloid leukemia (AML). Fluorizoline induced apoptosis in AML cells at concentrations in the low micromolar range. All primary samples were sensitive to fluorizoline irrespectively of patients' clinical or genetic features. In addition, fluorizoline inhibited the clonogenic capacity and induced differentiation of AML cells. Fluorizoline increased the mRNA and protein levels of the pro-apoptotic BCL-2 family member NOXA both in cell lines and primary samples analyzed. These results suggest that targeting PHBs could be a new therapeutic strategy for AML.

[1]  S. Swerdlow.  WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .

[2]  R. Levine,et al.  Molecular therapy for acute myeloid leukaemia , 2016, Nature Reviews Clinical Oncology.

[3]  H. Dombret,et al.  An update of current treatments for adult acute myeloid leukemia. , 2016, Blood.

[4]  T. Langer,et al.  A novel prohibitin-binding compound induces the mitochondrial apoptotic pathway through NOXA and BIM upregulation , 2015, Oncotarget.

[5]  A. Reinisch,et al.  Biology and Clinical Relevance of Acute Myeloid Leukemia Stem Cells. , 2015, Seminars in hematology.

[6]  Y. Min,et al.  Radotinib Induces Apoptosis of CD11b+ Cells Differentiated from Acute Myeloid Leukemia Cells , 2015, PloS one.

[7]  B. Smith,et al.  MLN4924 induces Noxa upregulation in acute myelogenous leukemia and synergizes with Bcl-2 inhibitors , 2015, Cell Death and Differentiation.

[8]  A. Strasser,et al.  The BCL-2 protein family, BH3-mimetics and cancer therapy , 2015, Cell Death and Differentiation.

[9]  S. Banerjee,et al.  Mitochondrial dependency in progression of acute myeloid leukemia. , 2015, Mitochondrion.

[10]  S. Waxman,et al.  Dihydroartemisinin and its derivative induce apoptosis in acute myeloid leukemia through Noxa-mediated pathway requiring iron and endoperoxide moiety , 2015, Oncotarget.

[11]  Christopher A. Miller,et al.  The Role of TP53 Mutations in the Origin and Evolution of Therapy-Related AML , 2014, Nature.

[12]  E. Estey,et al.  CME Information: Acute myeloid leukemia: 2014 update on risk-stratification and management , 2014 .

[13]  H. Handa,et al.  A trifluorinated thiazoline scaffold leading to pro-apoptotic agents targeting prohibitins. , 2014, Angewandte Chemie.

[14]  W. Blalock,et al.  Prohibitin 2 represents a novel nuclear AKT substrate during all‐trans retinoic acid–induced differentiation of acute promyelocytic leukemia cells , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  A. Letai,et al.  Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. , 2014, Cancer discovery.

[16]  James M. Bogenberger,et al.  BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies , 2014, Leukemia.

[17]  Peter E. Czabotar,et al.  Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy , 2013, Nature Reviews Molecular Cell Biology.

[18]  Paola Fazi,et al.  Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. , 2013, The New England journal of medicine.

[19]  N. Ribeiro,et al.  Prohibitin Ligands in Cell Death and Survival: Mode of Action and Therapeutic Potential , 2013, Chemistry & Biology.

[20]  S. Grant,et al.  Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism. , 2013, Cancer Research.

[21]  Yanfeng Liu,et al.  Lentiviral vector-mediated RNA interference targeted against prohibitin inhibits apoptosis of the retinoic acid-resistant acute promyelocytic leukemia cell line NB4-R1. , 2012, Molecular medicine reports.

[22]  A. Letai,et al.  Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML , 2012, Cell.

[23]  Erinna F. Lee,et al.  Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. , 2012, Genes & development.

[24]  N. Xi,et al.  Inactivation of SAG E3 Ubiquitin Ligase Blocks Embryonic Stem Cell Differentiation and Sensitizes Leukemia Cells to Retinoid Acid , 2011, PloS one.

[25]  B. Bauvois,et al.  Hyperforin Inhibits Akt1 Kinase Activity and Promotes Caspase-Mediated Apoptosis Involving Bad and Noxa Activation in Human Myeloid Tumor Cells , 2011, PloS one.

[26]  A. Theiss,et al.  The role and therapeutic potential of prohibitin in disease. , 2011, Biochimica et biophysica acta.

[27]  R. Navakauskienė,et al.  α-Dystrobrevin distribution and association with other proteins in human promyelocytic NB4 cells treated for granulocytic differentiation , 2011, Molecular Biology Reports.

[28]  I. Fleming,et al.  Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types , 2010, British Journal of Cancer.

[29]  T. Ley,et al.  Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia. , 2009, The Journal of clinical investigation.

[30]  T. Langer,et al.  Prohibitins and the functional compartmentalization of mitochondrial membranes , 2009, Journal of Cell Science.

[31]  S. Grant,et al.  Bim Upregulation by Histone Deacetylase Inhibitors Mediates Interactions with the Bcl-2 Antagonist ABT-737: Evidence for Distinct Roles for Bcl-2, Bcl-xL, and Mcl-1 , 2009, Molecular and Cellular Biology.

[32]  Nektarios Tavernarakis,et al.  Prohibitin and mitochondrial biology , 2009, Trends in Endocrinology & Metabolism.

[33]  R. Kofler,et al.  Noxa: at the tip of the balance between life and death , 2008, Oncogene.

[34]  M. Konopleva,et al.  HDAC inhibition by SNDX-275 (Entinostat) restores expression of silenced leukemia-associated transcription factors Nur77 and Nor1 and of key pro-apoptotic proteins in AML , 2013, Leukemia.

[35]  F. Luciano,et al.  Deregulation of the mitochondrial apoptotic machinery and development of molecular targeted drugs in acute myeloid leukemia. , 2008, Current cancer drug targets.

[36]  Adam J Mead,et al.  The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. , 2008, Blood.

[37]  John Calvin Reed,et al.  Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. , 2006, Cancer cell.

[38]  Jean McGowan-Jordan,et al.  ISCN 2013 : an international system for human cytogenetic nomenclature (2013) : recommendations of the International Standing Committee on Human Cytogenetic Nomenclature , 2005 .

[39]  J. Schouten,et al.  Expression profiling via novel multiplex assay allows rapid assessment of gene regulation in defined signalling pathways. , 2003, Nucleic acids research.

[40]  D. Howard,et al.  Preferential induction of apoptosis for primary human leukemic stem cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[41]  G. Ehninger,et al.  Analysis of Flt3-activating Mutations in 979 Patients with Acute Myelogenous Leukemia: Association with Fab Subtypes and Identification of Subgroups with Poor Prognosis , 2022 .

[42]  P. Thall,et al.  The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  John Calvin Reed,et al.  Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. , 1998, Blood.

[44]  H. Kaneko,et al.  Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. , 1996, Leukemia.

[45]  Daniel J Weisdorf,et al.  Acute Myeloid Leukemia. , 2015, The New England journal of medicine.

[46]  S. Fröhling,et al.  TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. , 2012, Blood.

[47]  T. Ikezoe,et al.  p53 is critical for the Aurora B kinase inhibitor-mediated apoptosis in acute myelogenous leukemia cells , 2010, International journal of hematology.

[48]  M. Konopleva,et al.  The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML , 2008, Leukemia.

[49]  M. Fricová,et al.  High expression of Bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. , 2002, Neoplasma.

[50]  G. Seitz,et al.  The prognostic value of Bcl-XL gene expression for remission induction is influenced by cytogenetics in adult acute myeloid leukemia. , 2001, Haematologica.